<DOC>
	<DOCNO>NCT00737360</DOCNO>
	<brief_summary>The purpose study determine whether TAS-106 effective patient recurrent metastatic head neck cancer refractory platinum base chemotherapy .</brief_summary>
	<brief_title>Phase II Study TAS-106 Treat Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Age 18 ≤ year old study entry Histologically confirm head neck carcinoma Received prior platinum base regimen develop disease progression recurrence Measurable disease accord RECIST guideline Radiological clinical evidence brain involvement leptomeningeal disease ≥ grade 2 peripheral neuropathy History another malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>